Business / Finance

RSS

Neutra acquires cutting-edge developer of smoke-free nutraceutical delivery systems

Neutra Corp. (OTCBB: NTRR), a fast-growing provider of all-natural wellness solutions, announced today that it acquired Diamond Anvil Designs (DA), a cutting-edge developer of smoke-free nutraceutical delivery systems.

11 Feb 2014

Triple-S announces consolidated revenues of $587.7 and net loss of $1.7 million for Q4 2013

Triple-S Management Corporation (NYSE: GTS), the leading managed care company in Puerto Rico, today announced consolidated revenues of $587.7 million and a consolidated net loss of $1.7 million for the three months ended December 31, 2013.

11 Feb 2014

Denver Health and North Colorado Med Evac announce provider agreement for air-medical transport

Denver Health and North Colorado Med Evac (a Med Trans Corp air medical program) are pleased to announce a contractual preferred provider agreement for air-medical transport and evacuation.

11 Feb 2014

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.

10 Feb 2014

Acentia announces acquisition of Business Computer Applications

Acentia, a premier provider of technology and management solutions, today announced it has acquired Atlanta-based Business Computer Applications, Inc., a provider of information technology (IT) services and solutions to the Centers for Disease Control and Prevention and other health agencies.

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

Applied Biologics now certified to provide goods, services to Federal government

Applied Biologics LLC, an integrated biotechnology company engaged in the development and commercialization of innovative biologic products derived from the placental tissues, is pleased to announce that Applied Biologics has been awarded a GSA Schedule 20 contract and is now certified to provide goods and services to the Federal government on a national scale.

9 Feb 2014

Henry Schein and ADA join forces to celebrate annual Give Kids A Smile Day

Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, together with 26 of the Company's valued supplier partners, join the American Dental Association (ADA) today to celebrate the ADA's annual Give Kids A Smile Day.

9 Feb 2014

Eleven Biotherapeutics announces pricing of initial public offering of common stock

Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.

6 Feb 2014

Highlights for first quarter of fiscal 2014 from MAXIMUS

MAXIMUS, a leading provider of government services worldwide, today reported financial results for its first quarter ended December 31, 2013.

6 Feb 2014

Mallinckrodt’s net sales increase $540.2M to 7.2% in first quarter 2014

Mallinckrodt plc, a global specialty pharmaceutical and medical imaging business, today reported results for the first quarter of fiscal 2014, which ended December 27, 2013. The company also announced revised guidance for fiscal 2014.

6 Feb 2014

Sound Physicians agrees to provide hospitalist services to Whidbey General Hospital

Sound Physicians, a leading hospitalist group based in Tacoma, Wash., has agreed to provide hospitalist services to Whidbey General Hospital beginning Feb. 5, 2014.

6 Feb 2014

Invacare reports net loss per share of $0.19 in fourth quarter 2013

Invacare Corporation today announced its financial results for the quarter and year ended December 31, 2013.

6 Feb 2014

UTHealth unveils country's first Mobile Stroke Unit

The University of Texas Health Science Center at Houston (UTHealth) Medical School, in partnership with Memorial Hermann-Texas Medical Center, has unveiled the country's first Mobile Stroke Unit.

6 Feb 2014

Neuland Laboratories announces financial results for third quarter of fiscal year 2014

Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2014, ended December 31, 2013.

5 Feb 2014

eInfochips launches Andromeda Reference Platform for medical imaging and telemedicine designers

The video processing system includes the system hardware and software that design teams need for fast time-to-application development

5 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that The Lancet has published the results of its Phase 2 clinical trial of its lead candidate, EMA401, in postherpetic neuralgia (PHN).

5 Feb 2014

Mayo Clinic, Minnesota Timberwolves, Lynx partner to extend Mayo Model of Care for patients

Mayo Clinic and the Minnesota Timberwolves and Lynx today announced a partnership which extends the Mayo Model of Care for patients in sports medicine to the Twin Cities.

5 Feb 2014

Business / Finance

Neutra acquires cutting-edge developer of smoke-free nutraceutical delivery systems

Triple-S announces consolidated revenues of $587.7 and net loss of $1.7 million for Q4 2013

Denver Health and North Colorado Med Evac announce provider agreement for air-medical transport

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Acentia announces acquisition of Business Computer Applications

pSivida announces financial results for second quarter 2014

Applied Biologics now certified to provide goods, services to Federal government

Henry Schein and ADA join forces to celebrate annual Give Kids A Smile Day

Eleven Biotherapeutics announces pricing of initial public offering of common stock

Highlights for first quarter of fiscal 2014 from MAXIMUS

Mallinckrodt’s net sales increase $540.2M to 7.2% in first quarter 2014

Sound Physicians agrees to provide hospitalist services to Whidbey General Hospital

Invacare reports net loss per share of $0.19 in fourth quarter 2013

UTHealth unveils country's first Mobile Stroke Unit

Neuland Laboratories announces financial results for third quarter of fiscal year 2014

eInfochips launches Andromeda Reference Platform for medical imaging and telemedicine designers

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Mayo Clinic, Minnesota Timberwolves, Lynx partner to extend Mayo Model of Care for patients

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News